Therapeutic Response

ER positive status confers therapeutic sensitivity to Tamoxifen in patients with Invasive Breast Carcinoma.

Statements

Source and description
Tamoxifen Monotherapy. NCCP National SACT Regimen. HSE. The Republic of Ireland's Health Service Executive (HSE) has approved tamoxifen for reimbursement as a treatment option for the adjuvant treatment of estrogen receptor positive breast cancer in patients who are pre- or post-menopausal women.
Tamoxifen Monotherapy. NCCP National SACT Regimen. HSE. The Republic of Ireland's Health Service Executive (HSE) has approved tamoxifen for reimbursement as a treatment option for estrogen receptor positive advanced breast cancer in pre- or post-menopausal women.